1. Home
  2. COLL vs JQC Comparison

COLL vs JQC Comparison

Compare COLL & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • COLL
    SELLHOLDBUYas of 2 days ago
  • JQC
    SELLHOLDBUYas of 2 days ago
  • Stock Information
  • Founded
  • COLL 2002
  • JQC 2003
  • Country
  • COLL United States
  • JQC United States
  • Employees
  • COLL N/A
  • JQC N/A
  • Industry
  • COLL Biotechnology: Pharmaceutical Preparations
  • JQC Finance Companies
  • Sector
  • COLL Health Care
  • JQC Finance
  • Exchange
  • COLL Nasdaq
  • JQC Nasdaq
  • Market Cap
  • COLL 910.2M
  • JQC 752.6M
  • IPO Year
  • COLL 2015
  • JQC N/A
  • Fundamental
  • Price
  • COLL $29.71
  • JQC $5.39
  • Analyst Decision
  • COLL Strong Buy
  • JQC
  • Analyst Count
  • COLL 5
  • JQC 0
  • Target Price
  • COLL $43.60
  • JQC N/A
  • AVG Volume (30 Days)
  • COLL 467.4K
  • JQC 714.6K
  • Earning Date
  • COLL 05-08-2025
  • JQC 01-01-0001
  • Dividend Yield
  • COLL N/A
  • JQC 11.13%
  • EPS Growth
  • COLL 43.56
  • JQC N/A
  • EPS
  • COLL 1.86
  • JQC N/A
  • Revenue
  • COLL $631,449,000.00
  • JQC N/A
  • Revenue This Year
  • COLL $19.43
  • JQC N/A
  • Revenue Next Year
  • COLL $3.34
  • JQC N/A
  • P/E Ratio
  • COLL $16.00
  • JQC N/A
  • Revenue Growth
  • COLL 11.41
  • JQC N/A
  • 52 Week Low
  • COLL $27.28
  • JQC $4.82
  • 52 Week High
  • COLL $42.29
  • JQC $5.65
  • Technical
  • Relative Strength Index (RSI)
  • COLL 48.90
  • JQC 41.09
  • Support Level
  • COLL $29.33
  • JQC $5.31
  • Resistance Level
  • COLL $30.84
  • JQC $5.58
  • Average True Range (ATR)
  • COLL 0.85
  • JQC 0.06
  • MACD
  • COLL 0.08
  • JQC -0.01
  • Stochastic Oscillator
  • COLL 50.11
  • JQC 36.67

Stock Price Comparison Chart: COLL vs JQC

COLL
JQC
JulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025051015202530354045COLL VS JQC

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

About JQC Nuveen Credit Strategies Income Fund Shares of Beneficial Interest

Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.

Share on Social Networks:

By browsing this website, you accept our Privacy Policy & Terms of Use